Drugs
New drug approved for chronic hepatitis C virus genotypes 1-6
- Therapy provides shorter treatment durations for many patients
-
FDA approves Mavyret for Hepatitis C Drug combines two chemotherapies into single formulation
- First treatment for patients with certain types of high-risk blood cancer
-
FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia First treatment approved for chronic graft versus host disease
- Condition is a complication of bone marrow and stem cell transplants
-
FDA approves treatment for chronic graft versus host disease Drug approved for certain patients with acute myeloid leukemia
- Treatment fills unmet need for some with bone marrow cancer
-
FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia
Navigate the Drugs Section
Bioterrorism, drug preparedness and natural disaster response
Drug Approvals and DatabasesDrug-Related Databases from FDA; Information on Drug Approvals
Drug Safety and AvailabilityMedication Guides, Drug Shortages, Drug Safety Communications and Other Safety Announcements
Development & Approval Process (Drugs)Conducting Clinical Trials, Types of Drug Applications, Forms and Submissions Requirements, Labeling Initiatives, Drug and Biologic Approval Reports
Guidance for Industry, Warning Letters, Postmarket Surveillance Programs, Rules and Regulations
News & EventsWhat's New on This Site, Drug Approval Listing, Meetings and Conferences
Science & Research (Drugs)Research by FDA Staff to Evaluate and Enhance the Safety of Drug Products
Resources for YouFor Consumers, Health Professionals, Industry
News and Announcements
Drug Safety
Program Areas
- Advisory Committees (Drugs)
- Generic Drugs
Guidances (Drugs) Pharmaceutical Quality Resources Regulation of Nonprescription Products Pediatric Product Development CDER Small Business & Industry Assistance (SBIA) - User Fees (BsUFA, GDUFA, PDUFA)
Warning Letters and Notice of Violation Letters to Pharmaceutical Companies
Spotlight
Recalls & Alerts
Approvals & Clearances
Stay Informed
Contact FDA
Division of Drug Information (CDER)
Office of Communications
10001 New Hampshire Avenue
Hillandale Building, 4th Floor
Silver Spring, MD 20993